World

U.S. anti-drug trafficking strategy "very misguided," says Mexican president

Sep 02, 2023

Mexico City [Mexico], September 2: The United States has adopted a "very misguided" strategy to fight drug trafficking at home while simultaneously allowing the consumption of some narcotics to get out of hand, Mexican President Andres Manuel Lopez Obrador said Thursday.
During his daily press conference, Lopez Obrador questioned, for example, why the U.S. National Basketball League allows marijuana use among its players.
"Why is there so much drug use in the United States? ... It's like a pandemic," Lopez Obrador told reporters at the National Palace in Mexico City. "It is very sad that 100,000 young people die each year due to the use of fentanyl."
The president again called for decision-makers in Washington to focus more on combating the root causes that lead to drug abuse, instead of applying coercive measures, especially against migrants, who "should not be blamed for everything."
The United States has suffered from a surge in opioid deaths over the past several years due to accidental overdoses, according to experts.
Some U.S. politicians have accused Mexico of being responsible for the illegal trafficking of fentanyl in its territory.
In response, Mexico has accused the U.S. government of not doing enough to combat drug abuse, especially among its youth.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025